Free Newsletter
ALSO NOTED: Sanofi sues to fight off Uroxatral imitators; Watson gets OK for generic AccuNeb
> Sanofi Aventis sued two generics makers--Teva Pharmaceuticals and Barr Laboratories--for infringing its patents on the prostate cancer drug Uroxatral. Report
> Watson Pharmaceuticals got the FDA nod for its generic form of the asthma medication AccuNeb. Report
> Sanofi Pasteur is scouting India, among other countries, for possible locations for a global manufacturing base, the Economic Times reports. Report
> AstraZeneca is poised to open an Israeli office and is seeking a local general manager there. Report
And Finally... Don't count on snagging your daily meds from a pharma facility. The thieves who got out of Genentech with human growth hormone are exceptions to the high-security rule--so much so that one expert likened a drug-company theft to stealing gold from Fort Knox. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: